ALK and non-small cell lung carcinoma: The data from KEYNOTE‐024 indicated that pembrolizumab monotherapy could provide meaningful improved patient outcomes over platinum‐based chemotherapy for advanced NSCLC patients with PD‐L1 TPS ≥ 50% but without sensitizing EGFR or ALK mutations in the first‐line treatment setting.